当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.

Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.

Abstract：

:From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin. Patients were eligible if they had progressive disease after either adjuvant (2 patients) or previous chemotherapy for metastatic disease (26 patients). Twenty-five patients (89.2%) had received previous anthracycline-based therapy. Predominant site of metastatic disease was visceral in 22 patients, bone in 2 patients, soft tissue in 4 patients, and the majority of patients (89.2%) had two or more sites of disease. The regimen was administered according to the following schedule: Mitoxantrone 9-12 mg/m2 i.v. on day 1; L-Leucovorin 150 mg i.v. over 1 hour before 5-Fluorouracil 350 mg/m2 i.v. push days, 1, 2 and 3. Courses were repeated every 21 days. Twenty-six patients were evaluable for response. We observed 2 complete responses, 5 partial responses with a median duration of 38 weeks (range 23-68). The objective response rate was 27% (95% C.I., 10% to 44%). Myelo-suppression was the most frequent toxicity, but it was mild in the majority of patients. Nine episodes of fever and neutropenia occurred in six patients but none of these episodes was fatal. No clinical evidence of cardiotoxicity was observed. At a median follow-up of 78 weeks, the median time to progression was 20.5 weeks and the median overall survival was 48 weeks. We conclude that this regimen is well tolerated and in our experience the objective response rate is similar to other salvage chemotherapy regimens.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Colozza M,Gori S,Mosconi AM,Anastasi P,Basurto C,Ludovini V,De Angelis V,Giansanti M,Tonato M

doi

10.1007/BF01806146

subject

Has Abstract

pub_date

1996-01-01 00:00:00

pages

277-82

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

38

pub_type

临床试验,杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.

    abstract：PURPOSE:Psychological resilience is an important ability for women with breast cancer to cope effectively with depression and anxiety. However, the demands of long-term hospital-based psychological rehabilitation interventions are not met in mainland China, where shorter hospital stays and longer home rehabilitation ar...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05368-9

    authors： Zhou K,Li J,Li X

    更新日期：2019-11-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract：PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4749-3

    authors： Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期：2018-07-01 00:00:00

  • Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.

    abstract：:Circulating tumor cells are commonly observed in the peripheral blood of advanced breast cancer patients. We tested the feasibility of tumor cell detection in the cerebrospinal fluid (CSF) and studied its clinical relevance in leptomeningeal metastasis (LM) of breast cancer. CSF samples were collected from 38 metastat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3610-1

    authors： Lee JS,Melisko ME,Magbanua MJ,Kablanian AT,Scott JH,Rugo HS,Park JW

    更新日期：2015-11-01 00:00:00

  • Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

    abstract：:Locally advanced breast cancer (LABC) is a good setting in which to monitor response to neoadjuvant chemotherapy, to downsize the tumor (which facilitates breast-conserving surgery), and to test newer agents in untreated patients. Eribulin (E) has shown activity in patients who have undergone previous taxane, anthracy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-015-3466-4

    authors： Abraham J,Robidoux A,Tan AR,Limentani S,Sturtz K,Shalaby I,Alcorn H,Buyse ME,Wolmark N,Jacobs SA

    更新日期：2015-07-01 00:00:00

  • Analysis of breast cancer in young women in the Department of Defense (DOD) database.

    abstract：PURPOSE:Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are se...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4615-8

    authors： Zimmer AS,Zhu K,Steeg PS,Wu A,Gatti-Mays ME,Soltani S,Perkins JG,Shao S,Brown D,Georg M,Hu H,Shriver CD,Lipkowitz S

    更新日期：2018-04-01 00:00:00

  • Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.

    abstract：BACKGROUND:Differences in de novo (dnMBC) and recurrent metastatic breast cancer (rMBC) presentation and survival over time have not been adequately described. METHODS:A retrospective cohort study, 1990-2010, with follow up through 2015 of dnMBC patients (stage IV at diagnosis) and rMBC patients with subsequent distan...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4529-5

    authors： Malmgren JA,Mayer M,Atwood MK,Kaplan HG

    更新日期：2018-01-01 00:00:00

  • Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial.

    abstract：:A potential advantage of primary over adjuvant chemotherapy in breast cancer survival had been proposed on theoretical grounds. In 1994, early results of the S6-trial comparing primary chemotherapy vs. adjuvant chemotherapy for operable breast cancer in 390 premenopausal patients had shown significant improvement in s...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006339918798

    authors： Broët P,Scholl SM,de la Rochefordière A,Fourquet A,Moreau T,De Rycke Y,Asselain B,Pouillart P

    更新日期：1999-11-01 00:00:00

  • Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO).

    abstract：:Germline mutations in BRCA1/2 confer a high risk of breast cancer (BC), but the magnitude of this risk varies according to various factors. Although controversial, there are data to support the hypothesis of allelic-risk heterogeneity. We assessed variation in BC risk according to the location of mutations recorded in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1655-3

    authors： Lecarpentier J,Noguès C,Mouret-Fourme E,Stoppa-Lyonnet D,Lasset C,Caron O,Fricker JP,Gladieff L,Faivre L,Sobol H,Gesta P,Frenay M,Luporsi E,Coupier I,GENEPSO.,Lidereau R,Andrieu N

    更新日期：2011-12-01 00:00:00

  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

    abstract：:The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an important role in tumor metastasis. We aimed to assess whether quantification of CTC-clusters provi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3636-4

    authors： Mu Z,Wang C,Ye Z,Austin L,Civan J,Hyslop T,Palazzo JP,Jaslow R,Li B,Myers RE,Jiang J,Xing J,Yang H,Cristofanilli M

    更新日期：2015-12-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract：:The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2035-3

    authors： Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期：2012-07-01 00:00:00

  • Long-term dysregulation of circadian and 17-beta estradiol-induced LH, prolactin and corticosterone secretion after dimethylbenz (a) anthracene administration in the Sprague-Dawley female rat.

    abstract：:A single intragastric administration of 7,12-dimethylbenz (a) anthracene (DMBA) has been shown, when given at 55-60 days of age, to induce mammary tumors in young cycling female Sprague-Dawley rats. The appearance of the tumors is preceded by a series of neuroendocrine disturbances of the hypothalamo-pituitary-gonadal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-0270-6

    authors： Yon de Jonage-Canonico MB,Lenoir V,Scholler R,Kerdelhué B

    更新日期：2005-07-01 00:00:00

  • The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

    abstract：PURPOSE:In Brazil, the available cancer registries are deficient in number and quality and, hence, little information is known regarding sociodemographic, clinicopathological characteristics, treatment patterns, and outcomes of breast cancer (BC) patients. We performed the AMAZONA III/ GBECAM 0115 study and in this ana...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05831-y

    authors： Rosa DD,Bines J,Werutsky G,Barrios CH,Cronemberger E,Queiroz GS,de Lima VCC,Freitas-Júnior R,Couto JD,Emerenciano K,Resende H,Crocamo S,Reinert T,Van Eyil B,Nerón Y,Dybal V,Lazaretti N,de Cassia Costamilan R,de Andrad

    更新日期：2020-10-01 00:00:00

  • The prognostic impact of age in different molecular subtypes of breast cancer.

    abstract：:Breast cancer is a heterogeneous entity composed of distinct molecular subgroups with different molecular and clinical features. We analyzed the association between molecular breast cancer subgroups, age at diagnosis, and prognosis in a compilation of publicly available gene expression datasets. Affymetrix gene expres...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3491-3

    authors： Liedtke C,Rody A,Gluz O,Baumann K,Beyer D,Kohls EB,Lausen K,Hanker L,Holtrich U,Becker S,Karn T

    更新日期：2015-08-01 00:00:00

  • Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.

    abstract：PURPOSE:A positive margin after breast conserving surgery has consistently been shown to be a significant predictor for ipsilateral breast tumor recurrence. Currently, there is no standard for intraoperative margin assessment during lumpectomy, and up to 20% of cases result in positive margins. MarginProbe is a device ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05773-5

    authors： LeeVan E,Ho BT,Seto S,Shen J

    更新日期：2020-08-01 00:00:00

  • Older women's experience with breast cancer treatment decisions.

    abstract：:The purpose of this study was to better understand older women's experience with breast cancer treatment decisions. We conducted a longitudinal study of non-demented, English-speaking women ≥ 65 years recruited from three Boston-based breast imaging centers. We interviewed women at the time of breast biopsy (before th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2921-y

    authors： Schonberg MA,Birdwell RL,Bychkovsky BL,Hintz L,Fein-Zachary V,Wertheimer MD,Silliman RA

    更新日期：2014-05-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract：:The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1014815112078

    authors： Hayden LJ,Satre MA

    更新日期：2002-03-01 00:00:00

  • Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.

    abstract：:Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006035603635

    authors： Yoo JY,Lessor T,Hamburger AW

    更新日期：1998-09-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract：:Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9317-6

    authors： Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期：2007-04-01 00:00:00

  • Double heterozygosity for germline mutations in BRCA1 and p53 in a woman with early onset breast cancer.

    abstract：:To report on a highly unusual case of a 20-year-old woman who presented with multifocal metaplastic breast cancer and was subsequently found to carry deleterious germline mutations in both BRCA1 and p53. Genetic testing was requested on an expedited basis to assist in surgical decision-making and BRCA1/2 and p53 genet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3011-x

    authors： Bell K,Hodgson N,Levine M,Sadikovic B,Zbuk K

    更新日期：2014-07-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study.

    abstract：:The objective of this nationwide prospective cohort study is to find out the risk of breast cancer (BC) in relatives of patients with multiple BCs by laterality and age at diagnosis of first BC. Having family history of single (HR 1.8; 95 % CI 1.8-1.9) or multiple (HR 2.7; 95 % CI 2.6-2.9) BC was associated with highe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2848-3

    authors： Kharazmi E,Chen T,Narod S,Sundquist K,Hemminki K

    更新日期：2014-02-01 00:00:00

  • Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

    abstract：:To evaluate differences in use of sentinel lymph node biopsy (SLNB) by age and race in Medicare recipients with early-stage breast cancer, we examined Surveillance, Epidemiology and End Results-Medicare linked data for women undergoing breast conserving surgery for stage I or II breast cancer, including axillary stagi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1398-1

    authors： Reeder-Hayes KE,Bainbridge J,Meyer AM,Amos KD,Weiner BJ,Godley PA,Carpenter WR

    更新日期：2011-08-01 00:00:00

  • CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.

    abstract：:We investigated the expression of -CXC chemokine ligand 13 (CXCL13) and its receptor -CXC chemokine receptor 5 (CXCR5) in 98 breast cancer (BC) patients with infiltrating duct carcinoma, out of which 56 were found lymph node metastasis (LNM) positive. Interestingly, co-expression of CXCL13 and CXCR5 showed a significa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2811-8

    authors： Biswas S,Sengupta S,Roy Chowdhury S,Jana S,Mandal G,Mandal PK,Saha N,Malhotra V,Gupta A,Kuprash DV,Bhattacharyya A

    更新日期：2014-01-01 00:00:00

  • Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin.

    abstract：:MCF-7 cells, a metastatic human breast carcinoma line, caused dose-dependent platelet aggregation in heparinized human platelet-rich plasma (PRP). MCF-7 tumor cell-induced platelet aggregation (TCIPA) was almost blocked by apyrase (0.5 U/ml) and completely inhibited by hirudin (5 U/ml). This TCIPA was unaffected by cy...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00665947

    authors： Chiang HS,Swaim MW,Huang TF

    更新日期：1995-03-01 00:00:00

  • Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan.

    abstract：:To further clarify risk factors for breast cancer in Japanese women, a self-administered questionnaire was completed by 157 cases with histologically confirmed breast cancer from 1989 to 1993 and by 369 age and residential area matched controls in Gifu, Japan. Conditional logistic regression model was used to assess t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1005745824388

    authors： Hu YH,Nagata C,Shimizu H,Kaneda N,Kashiki Y

    更新日期：1997-03-01 00:00:00

  • Weight changes after adjuvant treatment in Korean women with early breast cancer.

    abstract：BACKGROUND:Weight gain is a common problem in breast cancer patients and is reported to be associated with poorer survival. However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer. METHODS:The authors reviewed the records of 260 pat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9984-6

    authors： Han HS,Lee KW,Kim JH,Kim SW,Kim IA,Oh DY,Im SA,Bang SM,Lee JS

    更新日期：2009-03-01 00:00:00

  • Bulky DNA adducts and breast cancer risk in the prospective EPIC-Italy study.

    abstract：:The role of environmental carcinogen exposure in breast cancer development has long been suspected, but no specific association has been identified so far. A few molecular epidemiology studies reported that DNA adducts detected by different methods are associated with a modest increase of breast cancer risk. We aimed ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1472-8

    authors： Saieva C,Peluso M,Masala G,Munnia A,Ceroti M,Piro S,Sera F,Bendinelli B,Pala V,Sieri S,Tumino R,Giurdanella MC,Panico S,Mattiello A,Vineis P,Polidoro S,Matullo G,Palli D

    更新日期：2011-09-01 00:00:00

  • The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.

    abstract：:The mammalian target of rapamycin complex 1 (mTORC1) is a downstream of the PI3K/Akt pathway which affects cancer development. mTORC1 has many downstream signalling effectors that can enhance different cellular responses. This study aims to investigate the expression of mTORC1 in breast cancer (BC) and correlate it wi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3308-4

    authors： Jerjees DA,Negm OH,Alabdullah ML,Mirza S,Alkaabi M,Hameed MR,Abduljabbar R,Muftah A,Nolan CC,Green AR,Tighe PJ,Band V,Ellis IO,Rakha EA

    更新日期：2015-02-01 00:00:00

  • Effect of chemotherapy on survival in metastatic breast cancer.

    abstract：:In order to assess the impact of modern combination chemotherapy on overall survival of metastatic breast cancer patients, we retrospectively analysed survival data of those patients who presented with breast cancer and developed metastases at our clinic from 1971-78 inclusive. Our results indicate a trend towards imp...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806751

    authors： Paterson AH,Szafran O,Cornish F,Lees AW,Hanson J

    更新日期：1981-01-01 00:00:00

  • A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

    abstract：:Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients progressing after trastuzumab trea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-012-2003-y

    authors： Lin NU,Winer EP,Wheatley D,Carey LA,Houston S,Mendelson D,Munster P,Frakes L,Kelly S,Garcia AA,Cleator S,Uttenreuther-Fischer M,Jones H,Wind S,Vinisko R,Hickish T

    更新日期：2012-06-01 00:00:00